Chakravarti Bandana, Rajput Swati, Srivastava Anubhav, Sharma Lokendra Kumar, Sinha Rohit Anthony, Chattopadhyay Naibedya, Siddiqui Jawed Akhtar
Stem Cell/Cell culture lab Unit, Center for Advance Research, King George's Medical University, Lucknow, India.
Division of Endocrinology and Center for Research in Anabolic Skeletal Target in Health and Illness (ASTHI), CSIR-Central Drug Research Institute, Council of Scientific and Industrial Research, Lucknow, India.
Phytother Res. 2024 Dec;38(12):6062-6081. doi: 10.1002/ptr.8358. Epub 2024 Oct 31.
Female hormone-dependent cancers depend on estrogen for their growth. Numerous studies have explored the antitumor effect of dietary isoflavones on female hormone-dependent cancers. Still, few clinical evidence supports the use of isoflavones in female hormone-dependent cancer patients. This study was performed to examine the impact of dietary isoflavones on tumor growth of female hormone-dependent cancers and accelerate the transformation of research from bench to bedside. We searched PubMed Medline, Web of Science, and Google Scholar for relevant articles related to the effect of dietary isoflavone on tumor growth of experimental animal models of female hormone-dependent cancers from 1998 to 2024. The effects of dietary isoflavones on tumor growth were analyzed between the control and treatment groups using comprehensive meta-analysis software (CMA). We included 30 studies describing tumor growth focused on female hormone-dependent cancer types, including breast, ovarian, and uterine cancers. Overall, a pooled analysis revealed that dietary isoflavones reduced tumor volume (Hedge's g = -1.151, 95% CI = -1.717 to -0.585, p = 0.000) and tumor weight (Hedge's g = -2.584, 95% CI = -3.618 to -1.549, p = 0.000). On the other hand, dietary isoflavones increased tumor area (Hedge's g = 1.136, 95% CI = 0.752 to 1.520, p = 0.000). Dietary isoflavones have potential benefits and risks in female hormone-dependent cancers. Therefore, caution should be exercised when considering the intake of dietary isoflavones in female hormone-dependent cancer patients, particularly in the form of supplements.
女性激素依赖性癌症的生长依赖于雌激素。众多研究探讨了膳食异黄酮对女性激素依赖性癌症的抗肿瘤作用。然而，很少有临床证据支持在女性激素依赖性癌症患者中使用异黄酮。本研究旨在探讨膳食异黄酮对女性激素依赖性癌症肿瘤生长的影响，并加速研究从实验室到临床的转化。我们在PubMed Medline、Web of Science和谷歌学术上搜索了1998年至2024年期间与膳食异黄酮对女性激素依赖性癌症实验动物模型肿瘤生长影响相关的文章。使用综合荟萃分析软件（CMA）分析对照组和治疗组之间膳食异黄酮对肿瘤生长的影响。我们纳入了30项描述肿瘤生长的研究，这些研究聚焦于女性激素依赖性癌症类型，包括乳腺癌、卵巢癌和子宫癌。总体而言，汇总分析显示膳食异黄酮可减小肿瘤体积（Hedge's g = -1.151，95% CI = -1.717至-0.585，p = 0.000）和肿瘤重量（Hedge's g = -2.584，95% CI = -3.618至-1.549，p = 0.000）。另一方面，膳食异黄酮会增加肿瘤面积（Hedge's g = 1.136，95% CI = 0.752至1.520，p = 0.000）。膳食异黄酮在女性激素依赖性癌症中具有潜在的益处和风险。因此，在考虑女性激素依赖性癌症患者摄入膳食异黄酮时应谨慎，尤其是以补充剂形式摄入时。
